Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
For the treatment of rheumatoid arthritis and type 2 diabetes.
- Mechanism
- Curator reviewed
Potential mechanisms of action for HE3286 include regulation of NF-kB and increasing the production of regulatory T cells (Treg cells). NF-kB is a well-known transcription factor that controls the production of inflammatory cytokines such as TNF-a and interferon-g. Treg cells are referred to in the scientific literature as the peacekeepers of the body. Their role is to keep the immune system from attacking the body itself. Recent studies of Treg cells indicate that they may play a broader role than simply preventing autoimmune conditions. Manipulation of these cells may offer new treatments for conditions ranging from diabetes and organ rejection to cancer and infectious diseases. In type II diabetes, moderate inhibition of NF-kB improves glucose tolerance. [Press Release - Hollis-Eden Pharmaceuticals]
- Primary indication
- For the treatment of rheumatoid arthritis and type 2 diabetes.Curator reviewed
- Formula / weight
- C21H30O3 · 330.468 g/mol (avg)
- Code names
- HE-3286 · NE3107
Resolves to
JJKOQZHWYLMASZ-FJWDNACWSA-NSMILES[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C=C2C[C@@H](O)CC[C@]12CWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Bezisterim, and which of those have an active Phase 3 trial?